ArticlePloS one2026
Differences in life expectancy with and without disease using reported, measured, and combined estimates for hypertension and diabetes among older adults in Colombia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Colombia, estimates of diabetes and hypertension prevalence differ substantially depending on the source of measurement. These differences have important implications for understanding disease burden in later life, particularly as the population ages and chronic conditions become more prevalent.
methodsThis study uses nationally representative data from SABE-Colombia 2015 to estimate the prevalence and diseased life expectancy (DLE) with diabetes and hypertension among adults 60 and older. Prevalence was calculated using three measures: reported diagnosis, measured high-risk and a combined estimate that includes both indicators. We further disaggregated each disease into three categories: controlled, uncontrolled, and unaware. DLE was estimated using the Sullivan method.
resultsFor diabetes prevalence, the widest range between measures among men was at ages 80-84: 22.5% combined, 21.5% reported, and 6.7% measured. Among women the widest range occurred at ages 75-79: 34.4% combined, 32.0% reported, and 13.4% measured. An average man at age 60 was expected to live 3.8 years with diabetes using the combined measure, 3.5 years using reported diagnosis, and 1.5 years using measured data. An average women, at age 60, had a DLE with diabetes of 5.0 years using the combined measure, 4.6 years using reported measure, and 2.0 years using measured data. For hypertension prevalence, the widest range between measures among men occurred at ages 65-69: 64.8% combined, 47.3% reported, and 32.6% measured. Among women, the widest range also occurred at ages 65-69: 74.0% combined, 63.6% reported, and 28.2% measured. At age 60, men were expected to live 13.9 years with hypertension using the combined measure, compared with 10.5 years using reported diagnosis and 8.3 years using measured data. For women, DLEat age 60 was 16.7 years combined, 14.4 years reported, and 8.0 years measured.
conclusionWe found relatively high diabetes awareness and treatment. In contrast, for hypertension, reported diagnosis underestimated both prevalence and DLE compared to combined measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.